137 related articles for article (PubMed ID: 21668333)
1. Pharmacokinetics and pharmacodynamics of basal insulins.
Porcellati F; Bolli GB; Fanelli CG
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
[TBL] [Abstract][Full Text] [Related]
2. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
3. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
4. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
5. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
6. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
7. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
8. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
11. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
12. [The new insulins].
Krzentowski G
Rev Med Brux; 2005 Sep; 26(4):S241-5. PubMed ID: 16240869
[TBL] [Abstract][Full Text] [Related]
13. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
Gerich JE
Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
17. Euglycaemic glucose clamp: what it can and cannot do, and how to do it.
Heise T; Zijlstra E; Nosek L; Heckermann S; Plum-Mörschel L; Forst T
Diabetes Obes Metab; 2016 Oct; 18(10):962-72. PubMed ID: 27324560
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.
Bolli GB; Andreoli AM; Lucidi P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S43-52. PubMed ID: 21668336
[TBL] [Abstract][Full Text] [Related]
19. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]